Record Revenue and Gross Profit Revenue Increased 48% Year-Over-Year RICHLAND, WASHINGTON – November 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
Newsroom
Isoray To Announce First Quarter Fiscal 2020 Financial Results on November 12, 2019
Conference Call is Tuesday, November 12, 2019 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – October 31, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
Isoray Will Have Prominent Role at American Brachytherapy Society’s Annual Prostate Brachytherapy Workshop
RICHLAND, WASHINGTON – October 29, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR) announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is scheduled to take place...
Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results
Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, WASHINGTON – September 24, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...
A Decade of Data Shows the Value of Isoray’s Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment
Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2% Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date RICHLAND, WASHINGTON – September 18, 2019 –A recent publication is drawing attention for its positive report on a...
Isoray To Announce Fourth Quarter and Year End 2019 Financial Results on September 24, 2019
Conference Call is Tuesday, September 24, 2019, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting
RICHLAND, WASHINGTON – September 10, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced today that it will spotlight the growing cancer...
Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies
RICHLAND, WASHINGTON – August 13, 2019 – Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.'s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for cancer...
Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society’s Annual Meeting
New Brand Identity to Be Unveiled Thursday, June 13 RICHLAND, WASHINGTON – June 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced...
Isoray Announces Record Third Quarter Fiscal 2019 Financial Results
Record Revenue and Gross Profit Revenue Increased 22% Year-Over-Year RICHLAND, WASHINGTON – May 9, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...
Isoray To Announce Third Quarter Fiscal 2019 Financial Results on May 9, 2019
Conference Call is May 9 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 1, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it...
Isoray Collaborates With Texas Oncology to Fill Void in Training Programs For Next Generation of Brachytherapists
RICHLAND, WASHINGTON – April 16, 2019 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced a new training collaboration with Texas Oncology. The...
Isoray Announces Second Quarter Fiscal 2019 Financial Results
Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year RICHLAND, WASHINGTON - February 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
Investor Relations:
Mark Levin
Media and Public Relations:
Sharon Schultz
(302) 539-3747
View the Press Release Archive